SMO and skin basal cell carcinoma: These results provide quantitative insights into the signalling network of SHH/SMO involved in BCC, and suggest that a combined inhibition with different dosages of SMO, PDE and PI3K/Akt inhibitors may be required to tackle drug-resistant BCC.